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Abstract  18 
The P[19] genotype belongs to the P[II] genogroup of group A rotaviruses (RVs). 19 
However, unlike the other P[II] RVs that mainly infects humans, P[19] RVs commonly 20 
infect animals (porcine), making P[19] unique to study RV diversity and host ranges. 21 
Through in vitro binding assays and saturation transfer difference (STD) NMR, we found 22 
that P[19] could bind mucin cores 2, 4, and 6, as well as type 1 histo-blood group 23 
antigens (HBGAs). The common sequences of these glycans serve as minimal binding 24 
units, while additional residues, such as the A, B, H, and Lewis epitopes of the type 1 25 
HBGAs, can further define the binding outcomes and therefore, likely the host ranges 26 
for P[19] RVs. This complex binding property of P[19] is shared with those of the other 27 
three P[II] RVs (P[4], P[6] and P[8]) in that all of them recognized the type 1 HBGA 28 
precursor, although P[4] and P[8], but not P[6], also bind to mucin cores. Moreover, 29 
while essential for P[4] and P[8] binding, the addition of the Lewis epitope blocked P[6] 30 
and P[19] binding to type 1 HBGAs. Chemical shift NMR of P[19] VP8* identified a 31 
ligand binding interface that has shifted away from the known RV P-genotype binding 32 
sites but is conserved among all P[II] RVs and two P[I] RVs (P[10] and P[12]), 33 
suggesting an evolutionary connection among these human and animal RVs. Taken 34 
together, these data are important for hypotheses on potential mechanisms for RV 35 
diversity, host ranges, and cross-species transmission.  36 
Importance 37 
In this study, we found that this P[19] strain and other P[II] RVs recognize mucin cores 38 
and the type 1 HBGA precursors as the minimal functional units and that additional 39 
saccharides adjacent to these units can alter binding outcomes and thereby possibly 40 
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host ranges. These data may help to explain why some P[II] RVs, such as P[6] and 41 
P[19], commonly infect animals but rarely humans, while others, such as the P[4] and 42 
P[8] RVs, mainly infect humans and are predominant over other P genotypes. 43 
Elucidation of the molecular bases for strain-specific host ranges and cross-species 44 
transmission of these human and animal RVs is important to understand RV 45 
epidemiology and disease burden, which may impact development of control and 46 
prevention strategies against RV gastroenteritis. 47 
Introduction 48 
Rotaviruses (RVs) are the principal cause of severe diarrhea in children, responsible for 49 
approximately 200,000 deaths in children younger than 5 years old worldwide in 2011 50 
(1-3). It has been shown that RV attachment to cell surface carbohydrates, mediated by 51 
the VP8* domain of the VP4 spike protein, is the important first step for successful 52 
infection (4-7). RVs are diverse in recognizing different receptors, causing infections in 53 
humans and different animal species. For example, early studies showed that infection 54 
with some animal RVs relies on the terminal sialic acid (SA) and are sialidase-sensitive, 55 
but the majority of human and animal RVs are sialidase-insensitive (8-12). However, a 56 
recent study indicated that a sialidase-insensitive human RV, Wa (P[8]), recognizes an 57 
internal SA residue (13). In addition, other host cell surface molecules, such as the heat 58 
shock cognate protein 70 (14-16) and integrins (17-19), have been identified as 59 
potential RV receptors, although their precise roles in RV attachment, penetration, and 60 
pathogenesis in host cells remain elusive.  61 
The recent findings that almost all major RV genotypes in the P[II]-P[IV] genogroups 62 
infect humans and recognize HBGAs (20-27) have led to a plausible hypothesis that 63 
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HBGAs are important host factors or cellular receptors for human RVs. Direct evidence 64 
for HBGA-RV interaction has been obtained by resolving the VP8* protein crystal 65 
structures for two human RVs (P[14] and P[11]) in complex with their HBGA 66 
oligosaccharide ligands (21, 22). The association between RV infection and a child’s 67 
secretor status has also been observed through epidemiologic studies (28-31). 68 
Together, these findings suggest that HBGAs play important roles in RV infection and 69 
pathogenesis.  70 
Although direct co-crystal data remain lacking, recognition of HBGAs by the most 71 
prevalent human rotavirus genotypes of P[4], P[6] and P[8] has been reported by in vitro 72 
binding assays. For example, the VP8*s of the human P[8] and P[4] RVs recognize the 73 
Lewis b and H-type 1 HBGAs, while the P[6] RVs bind the H type 1 only (23). However, 74 
a STD-NMR based study showed that while the human P[4] (strain DS-1) and P[6] 75 
(strain RV-3) RV VP8* could bind the A-type HBGAs with the involvement of the α1-2 76 
fucose, the VP8* of the P[8] human strain Wa did not recognize the A and the Lewis b/H 77 
type 1 antigens (20). On the other hand, a binding study with a human milk glycan 78 
library confirmed the binding of the P[6] (RV-3) VP8* to the terminal type 1 HBGA 79 
sequences with or without the H epitope but without the Lewis epitope and an additional 80 
internal Lewis x determinant (32).  81 
The group A RVs are diverse and have been divided into 37 P genotypes (P[1] – P[37]) 82 
in five P genogroups (P[I] – P[V]) based on sequences of the viral surface spike proteins 83 
VP4 or VP8* (25, 33) (Fig 1). While the majority of RVs exclusively or nearly exclusively 84 
infect either humans or particular animal species, others appear to commonly infect 85 
both humans and animals (P[6], P[9], P[11], and P[14] in P[II]-P[IV]) or infect mainly 86 
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animals with occasional infection of both humans and animals (P[1], P[2], P[3], P[7], 87 
P[10], and P[28] in P[I]) (Fig 1). Mechanisms for cross-species transmission have been 88 
suggested for some RVs, such as the P[III] RVs that can infect both humans and 89 
animals probably via recognition of the A antigens shared by humans and wild and 90 
domestic animals (25). In addition, the P[11] RVs recognize HBGA precursors or 91 
backbones whose chain length and branching are developmentally controlled in 92 
neonates and young infants (24, 26). These carbohydrates are evolutionarily conserved 93 
between humans and some animals. However, the reasons behind P[1], P[2], P[3], P[7], 94 
P[10], and P[28] RVs infection in animals or occasionally both human and animals 95 
remain unknown, limiting our understanding of RV epidemiology and thus, the ability to 96 
develop rational prevention strategies.  97 
In this study, we characterized a P[19] RV that commonly infects animals (porcine), but 98 
rarely humans (Fig.1). A unique binding property to the di-saccharide core structure 99 
(GlcNAcβ1-6GalNAc) of mucin cores 2, 4, and 6 and the extended terminal type 1 100 
HBGA tri-saccharide (Galβ1-3GlcNAcβ1-3Gal) was identified for an overlapping binding 101 
interface. This P[19] RV binding interface differed from known ones but appeared to be 102 
conserved among P[II] RVs and two P[I] RVs (P[10] and P[12]) (Fig.1). Additional 103 
saccharides surrounding the core sequences also impact the glycan binding specificities 104 
for these RVs. This may explain the observed diversity in binding specificity, host 105 
ranges, and possibly pathogenicity of RVs in different human populations and animal 106 
species.  107 
Materials and Methods 108 
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Expression and purification of VP8* proteins in E. Coli. The VP8* sequences 109 
(amino acids 46-231) from a human RV P[19] (GenBank accession number: 110 
DQ887060) was expressed in E. coli BL21 and purified by GST-tag affinity purification, 111 
as described previously (25). Recombinant VP8* proteins of other P[II] RVs (P[4], P[6] 112 
and P[8]) and a P[10] RVs were also purified using the same expression system. 15N- or 113 
15N,13C-labeled P[19] VP8* proteins were also made for the NMR studies using the 114 
same E. coli culture procedures with the addition of 15N-minimal growth medium (22 mM 115 
KH2PO4, 50 mM Na2HPO4, 8.5 Mm NaCl, 0.1 mM CaCl2, 2 mM MgSO4, 1x BME 116 
vitamins, 18 mM 15NH4Cl, and 22 mM Glucose) or 15N,13C-minimal growth medium 117 
supplied with 22 mM 13C-Glucose (20). The GST tag of the labeled VP8* proteins was 118 
removed for the NMR study by cutting with thrombin (Sigma-Aldrich Co., St. Louis, MO) 119 
followed by FPLC gel filtration to collect the VP8* protein fractions and concentrated by 120 
ultracentrifugation. The purified VP8* proteins were stored at -80 oC until needed. 121 
Binding of P[19] VP8* to human saliva, human milk, and porcine mucins. A set of 122 
previously characterized adult saliva samples with known ABO, secretor, and Lewis 123 
phenotypes were used in binding assays with the GST-VP8* fusion proteins (23). In 124 
addition, a set of saliva samples from neonates and young infants at different ages in 125 
the first year of lives described in a previous study (24) was studied for age-specific host 126 
ranges of P[6] RVs. A pooled human milk sample from the Cincinnati human milk bank 127 
(34) and a commercial porcine mucin (Sigma) were also tested for binding to P[19] 128 
VP8*. The carbohydrate profiles for the human milk and porcine mucin have been 129 
determined in our previous studies (25, 34).  130 
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Glycan array screening and ELISA-based oligosaccharide binding assay. Initial 131 
ligand screenings for P[19] VP8* was performed by the Protein-Glycan Interaction Core 132 
of CFG (Consortium for Functional Glycomics) (The glycan library information was 133 
available from the website http://www.functionalglycomics.org/). The recombinant GST-134 
VP8* proteins were applied to individual glycan arrays at a protein concentration of 200 135 
µg/ml and the bound GST-VP8* were detected using a fluorescent-labeled anti-GST 136 
monoclonal antibody. Relative fluorescent units (RFU) of each glycan were calculated to 137 
rank the reactivity in the interaction with P[19] VP8*. A further microarray analysis was 138 
performed at the carbohydrate microarray facility of the Glycosciences Laboratory at the 139 
Imperial College, London, the United Kingdom, using a focused array of sequence-140 
defined glycan probes arrayed as lipid-linked probes (35). The probes are prepared 141 
from reducing oligosaccharides by reductive amination with the amino lipid, 1,2-142 
dihexadecyl-sn-glycero-3-phosphoethanolamine, designated DH. The P[19] VP8* was 143 
overlaid at 50 µg/ml, followed by rabbit anti-GST antibody Z-5 (Santa Cruz, Dallas, TX), 144 
and biotinylated anti-rabbit IgG (Sigma). Binding was detected with Alexa Fluor-647-145 
labelled streptavidin (Molecular Probes, Eugene, OR). The probes have been described 146 
previously (36, 37) except for DFiLNO, a difucosylated decasaccharide received from 147 
Dextra as an unknown impurity of TFiLNO (1-2,-2,-3) and characterized by ES-CID-148 
MS/MS (W Chai, unpublished). 149 
The ELISA-based oligosaccharide binding assays were carried out as previously 150 
described (38). Oligosaccharides used in the study included biotin-labeled PAA-151 
conjugates obtained from CFG and Glycotech (GlycoTech, Inc., Gaithersburg, MD), and 152 
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8 
biotin-labeled BSA conjugates of A, B, and H type 1 to type 4, kindly provided by Dr. 153 
Todd L. Lowary.  154 
Two-dimensional heteronuclear single quantum correlation (1H-15N-HSQC) NMR 155 
experiments. Titrations of P[19] VP8* with mucin core 2 (kindly provided by Dr. James 156 
Paulson) and LNFPI (V-lab) were followed by in 1H-15N-HSQC experiments and used to 157 
calculate solution dissociation constants (KD values) for binding of the two ligands to  158 
P[19] VP8*. The KD  values were defined as KD =[VP8*][Ligand]/[VP8*-Ligand], where 159 
[VP8*-Ligand] refers to the concentration of the complex of VP8* and the glycan ligand, 160 
and [VP8*] and [Ligand] are the concentrations of free protein and ligand. NMR data 161 
were collected at 20 oC with samples of ~300 µL of Tris NMR buffer (10 mM Tris-HCl, 162 
100 mM NaCl, 1 mM EDTA, 10% D2O, pH 8.0) in 5 mm Shigemi NMR tubes on a 600 163 
MHz Bruker Avance III spectrometer. Samples of 0.25 mM 15N-labeled VP8* were 164 
titrated with each ligand at 0, 0.1, 0.3, 0.5, 1.0, 1.4, 1.9, 2.7, 4.3, and 6 mM, and 2-D 1H-165 
15N-HSQC spectra were acquired after each titration step. Spectra were processed with 166 
NMRPipe software (39) and analyzed with Sparky 167 
(http://www.cgl.ucsf.edu/home/sparky) . The weighted chemical shift change upon 168 
titration was determined for 10 strongly affected backbone amide peaks that were not 169 
overlapped according to the following formula for chemical shift change (CSC) (40) : 170 
CSC= Σ {[(ΔδHN)2 + (ΔδN/6.5)2]} 1/2, ΔδHN = δHNfree - δH
N
bound and, ΔδN = δNfree - δNbound, 171 
where δNfree and δNbound are the amide 15N chemical shifts in the absence and presence 172 
of ligand; δHNfree and δH
N
bound are the backbone amide hydrogen chemical shifts, 173 
respectively. The concentration of free ligand, [L-free], was determined by [L-free] = [L-174 
total] - (1/f) × [P-total], where f is the fraction of VP8* in the bound state is CSC/CSC-175 
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9 
max, and [L-total] and [P-total] are the total concentrations of ligand and protein at each 176 
titration. The CSC-max and KDs were determined by fitting the CSC/CSC-max at each 177 
ligand titration versus the [L-free] to the equation f = [L-free]/( KD +[L-free]), with the 178 
variables CSC-max and KD. The [L-free] values were calculated with the updated CSC-179 
max, and this process was repeated until there were no further changes. The error bars 180 
for KD were determined based on the average and standard deviation of the 10 peaks 181 
that had their CAC/CSC-max vs [L-free] plotted and fit to KD in the in the same way.   182 
P[19] VP8* chemical shift assignments.  In order to assign the backbone chemical 183 
shifts, 2-D and 3-D NMR data were collected for ~300 µL of 1.1 mM 15N-13C-labeled 184 
P[19] VP8* in Tris NMR buffer at 20 oC on 600 MHz Varian Inova, 600 MHz Bruker 185 
Avance III, and 850 MHz Bruker Avance II NMR spectrometers equipped with 186 
conventional 5-mm HCN probes. Backbone 1H, 13C, and 15N resonance assignments 187 
were made using the PINE server and then corrected and completed manually based 188 
on following 3-D spectra (41): HNCACB, CBCA(CO)NH, HNCO, HNCA, HN(CO)CA, 189 
HN(CA)CO, HBHA(CO)NH, and 15N-edited NOESY-HSQC (τm = 100 ms). Backbone 190 
assignments were 91% complete for residues 63-225, and only 5-10 HN cross peaks 191 
could not be assigned. However, none of the unassigned peaks shifted in the titration 192 
studies. 193 
Ligand chemical shift assignments. Chemical shift assignments of mucin core 2 and 194 
LNFPI were achieved by analysis of 2-D 1H-13C HSQC, HMBC, HSQC-TOCSY, 1H-1H 195 
COSY, TOCSY, and NOESY, and 1-D 1H NMR experiments recorded at 20 oC and 196 
referenced to internal TSP(20, 42). The NMR samples were 2 mM mucin core 2 in Tris 197 
NMR buffer and 5 mM LNFPI in phosphate NMR buffer (20 mM sodium phosphate, 100 198 
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mM NaCl, 10% D2O), both at pH 8.0. Chemical shift assignments for LNFPI were in 199 
agreement with published values (43), although differences can be attributed to pH, 200 
temperature, and referencing variations. 201 
STD NMR experiments. All saturation transfer difference (STD) NMR spectra were 202 
acquired in Shigemi Tubes (Shigemi, USA) with a Bruker 600 MHz Avance III 203 
spectrometer at 10 oC using a conventional HCN probe and the TopSpin 3.1 pulse 204 
sequence STDDIFFGG19.3. The NMR sample for mucin core 2 in complex with P[19] 205 
VP8* was prepared with 200 uM protein and 6.0 mM ligand in a final volume of 300 μL 206 
Tris NMR buffer. The LNFPI STD sample was prepared with 130 μM P[19] VP8* and 207 
6.6 mM LNFPI in a final volume of 300 μL of phosphate NMR buffer. This results in total 208 
protein-ligand ratios of 1:35 and 1:50, for the mucin core 2 and LNFPI samples, 209 
respectively. The protein resonances were saturated at 0 ppm with a cascade of 40 210 
Gaussian shaped pulses with duration of 50 ms resulting in a total saturation time of 2 211 
sec. The off-resonance saturation was applied to 30 ppm and 1024 experiments were 212 
acquired for each with a 5 sec recycle delay. A spin-lock filter with strength of 10 kHz 213 
and duration of 100-200 ms was applied to suppress the broad protein resonance 214 
signals, and Watergate 3-9-19 was used to suppress the residual water signal. The STD 215 
spectra were obtained by subtracting the on-resonance spectrum from the off-216 
resonance reference spectrum. STD amplification factors were determined by the 217 
equation (Io - Isat) / Io, where Io and Isat are the intensity of the signals in the reference 218 
and saturated spectra, respectively, and the normalized STD amplification percentage 219 
was determined by dividing by the largest STD amplification factor for each ligand. The 220 
protons with the largest STD amplification percentage along with data from the 2-D 221 
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STD-tocsy spectrum, which was used to resolve overlap from the 1D spectra, were 222 
used to assign the binding epitopes.   223 
Homology modeling of P[19] VP8* and site-directed mutagenesis. A homology 224 
model of the P[19] VP8* protein was built based on the X-ray crystal structure of DS1 225 
strain of RVs (PDB ID: 2AEN) as the template by SWISS-MODEL automated protein 226 
structure homology-modelling server (http://swissmodel.expasy.org/). Mutant VP8* 227 
proteins with single amino acid substitution were constructed from template wild type 228 
VP8* constructs using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La 229 
Jolla, CA).  230 
Virus propagation, inhibition, and infectivity assays. A P[19] RV (G9P[19]) was 231 
adapted from a positive stool sample obtained from Taiwan CDC collected on Dec.17, 232 
2014  by multiple blind passages on the MA104 cells. The identity of the strain was 233 
confirmed by RT-PCR and sequencing following detection of viral replication in the cell 234 
culture by ELISA using Rotaclone kit (Meridian Bioscience, OH, USA).  The cell-culture 235 
adapted P[19] RVs were then used for inhibition assays with human milk, neonate 236 
saliva, porcine mucin FPLC fractions as well as the oligosaccharides of LNFPI and 237 
mucin core 2 using procedures described previously (24). In brief, the P[19] viruses (at 238 
300 fluorescent forming units (FFU)/10 µl) were pre-incubated with different inhibition 239 
reagents for 30 min.  After rinsing twice with serum-free DMEM and chilling of all 240 
reagents and the 24-well plates on ice, duplicated wells of confluent MA104 monolayer 241 
were inoculated with the virus-oligosaccharide or virus-saliva/milk mixtures on ice with 242 
continuous rocker platform agitation for 1 h. The inocula were then removed and the 243 
cells were washed twice with ice-cold serum-free DMEM. The plates were then placed 244 
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back to the 37 oC incubator for 18 to 20 h prior to quantification of infected cells by 245 
immunofluorescence with a rabbit anti-rotavirus antibody followed by a FITC-labelled 246 
goat anti-rabbit secondary antibody. 247 
 248 
Results 249 
The P[19] VP8* binds human saliva, human milk, and porcine mucin.  Our study 250 
started with in vitro binding assays of P[19] VP8* to human milk, human saliva, and 251 
porcine mucin for the detection of potential host receptor ligands. The P[19] VP8* 252 
proteins bound the high molecular weight gel-filtration fractions of human milk and 253 
porcine mucins (Fig.2a, 2b), as well as a group of human saliva samples with variable 254 
binding profiles among saliva donors (Fig. 2c), indicating the existence of receptors or 255 
ligands in these natural host glycan reservoirs. The binding pattern of the P[19] VP8* to 256 
human saliva differed from the P[4], P[6], and P[8] RVs (23), where the P[19] VP8* 257 
bound a low proportion of samples (12%) with no correlation to the ABH or Lewis types 258 
of the saliva donors (Fig. 2c), suggesting that a unique, low-abundant carbohydrate may 259 
be responsible for the low prevalence of P[19] in human populations.   260 
P[19] VP8* recognizes mucin cores and the type 1 HBGA precursor. To define 261 
specific carbohydrates recognized by P[19] VP8*, a glycan array analysis was 262 
performed by the Consortium of Functional Glycomics (CFG) against a glycan library 263 
containing 610 mammalian glycans. Binding signals arose for a group of glycans 264 
containing the type 1 HBGAs and/or mucin cores 2, 4, and 6 (Fig. 3a). Further binding 265 
assays with different HBGA- and mucin core-related glycans (Fig. 3b-f) confirmed the 266 
glycan array results. For example, among the four types (types 1-4) of HBGAs tested, 267 
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13 
the P[19] VP8* bound only the type 1 antigens (Fig. 3b-e). This result was further 268 
confirmed by a focused neoglycolipid-based array with pair-wise comparisons of 269 
oligosaccharide sequences that differed only in linkages between residues in each of 270 
the type 1 (Galβ1-3GlcNAc) and type 2 (Galβ1-4GlcNAc) glycans (Fig. 3g). These 271 
results indicate that only glycans containing the terminal Galβ1-3GlcNAc sequence 272 
were recognized by P[19], further supporting the specificity toward type 1 sequences for 273 
P[19].   274 
Additional modifications of the type 1 disaccharides of Galβ1-3GlcNAc affected the 275 
P[19] VP8* binding signals. For example, the terminal A or B residues, as well as the 276 
α1,2-linked fucose, could enhance the binding signals, while the Lewis epitope (α1,4-277 
linked fucose) abolished binding (Fig. 3b). In vitro binding assays of the P[19] VP8* to 278 
mucin core glycans (mucin cores 1 to 8) also confirmed the glycan array results, with 279 
the positive binding signals observed only in those containing the disaccharide 280 
GlcNAcβ1-6GalNAc, while further additions of residues GlcNAc β1-3 (mucin core 4) or 281 
Gal β1-3 (mucin core 2) linking to GalNAc enhanced the binding (Fig. 3f).  282 
The ligand binding specificity of the P[19] VP8* was further characterized by STD-NMR.  283 
Data for a type 1 HBGA pentasaccharide LNFPI (Fucα1-2Galβ1-3GlcNAcβ1-3Gal) 284 
demonstrated that the extended type 1 chain of an internal Gal (Fucα1-2Galβ1-285 
3GlcNAcβ1-3Gal) is also involved in the interaction with P[19] VP8*, in addition to the 286 
GlcNAc and the terminal (H) fucose (Fig. 4a-b). Similarly, STD-NMR of P[19] VP8* with 287 
mucin core 2 showed a strong interaction with the disaccharide GlcNAcβ1-6GalNAc, in 288 
which the GlcNAc residue was highly involved (Fig. 4c-d).  289 
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P[19] RV replication was inhibited by human saliva, human milk, porcine mucin, 290 
and LNFPI glycans. To examine the biologic significance of reactive glycan ligands for 291 
P[19] RVs, viral replication inhibition assays were performed on a human P[19] RV. 292 
P[19] RV titers were significantly reduced following incubation of the viruses with saliva, 293 
porcine mucin fractions (gel-filtration), and human milk samples that previously bound 294 
P[19] VP8* (Fig. 5a-b). In contrast, the virus titers were not reduced after treatment with 295 
samples that did not bind to P[19] VP8* previously (Fig. 5b). Following treatment with 296 
human milk, a typical dose-dependent reduction, with up to 77.2% of infectivity 297 
decrease was observed (Fig. 5b). Similar blocking effects have also been observed for 298 
the BSA conjugated LNFPI (Fig. 5c), whereas the non-conjugated mucin core 2 did not 299 
result in an obvious inhibitory effect (Fig. 5c), possibly due to the monovalence of the 300 
core 2 oligosaccharide used in the experiment.  301 
The P[19] VP8* ligand binding interface differed from previously known ones. To 302 
explore the glycan binding interface for P[19] RVs, NMR titration studies of mucin core 2 303 
and LNFPI were conducted to measure chemical shift changes in backbone amide 304 
resonances followed by 1H-15N heteronuclear single quantum coherence (HSQC) 305 
spectra. All backbone chemical shifts files were available from BioMagResBank 306 
database (accession number 25441). Although LNFPI caused slightly more amino acid 307 
perturbations, the residues with HSQC chemical shift perturbations for mucin core 2 and 308 
LNFPI largely overlapped (Fig. 6a-d), suggesting a common interface for the two 309 
ligands. Interestingly, the KD-values of the HSQC chemical shift perturbation for P[19] 310 
VP8* to mucin core 2 (KD = 0.4 mM) were higher than those to LNFPI (KD = 2.6 mM) 311 
(Fig. 6e), indicating the affinity of P[19] VP8* to mucin core 2 was higher than to LNFPI. 312 
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More than half of the residues did not reveal significant perturbations upon sequential 313 
addition of the ligands, suggesting that there were no effects due to buffer changes. 314 
Besides, NMR of P[19] VP8* with the glycan of LacNAc (Galβ1-4GlcNAc) were 315 
conducted as a control experiment and no clear chemical shifts on P[19] VP8* was 316 
observed, which further confirmed the specificity of mucin core 2 and LNFPI to P[19] 317 
VP8*. 318 
More than 90% of chemical shift perturbations occurred for a group of amino acids 319 
scattered in a location near the previously identified SA- and A-HBGA binding interfaces 320 
(11, 21, 44) (Fig. 7a-b). Mutants with single-amino acid changes at seven of these 321 
perturbed residues (W81, L168, H170, W175, T186, R211, and E214) which could 322 
constitute a binding interface of P[19] resulted in completely loss of binding to mucin 323 
core glycans (Fig. 7a-d). In addition, besides the above mentioned seven amino acids, 324 
we noted that single-amino acid mutations at another two perturbed residues (T218 and 325 
Y189) also eliminated binding of P[19] VP8* to LNFPI (Fig. 7e-f). However, mutations at 326 
three other perturbed amino acids (D188, Y189, and S190) in the corresponding SA or 327 
A-HBGA binding interface, revealed only minor reductions in P[19] binding to mucin 328 
cores and LNFPI, while none of other amino acids that constitutes the SA/A-HBGA 329 
binding interface had effect on the binding of P[19] RV to either mucin cores or LNFPI. 330 
Together, these data indicate that P[19] uses a new, but related, glycan binding 331 
interface that significantly shifted away from the previously known sites. 332 
Superimposition comparison of this glycan binding site with those for P[3], P[14], and 333 
P[11] supported our observations (Fig. 7b, data not shown).  334 
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Sequence alignment showed that all P[19] strains had identical amino acid 335 
compositions on the deduced ligand binding site (Fig.8). Besides, alignment of the 336 
group A RV VP8* sequences showed that the amino acids of the deduced ligand 337 
binding interface of the P[19] RVs are conserved among all other three P[II] RVs (P[4], 338 
P[6], and P[8]) (Fig.8), suggesting a common host factor or receptor may be responsible 339 
for maintenance of the P[II] genogroup. In addition, among the diverse P[I] genogroup 340 
that cause diseases in different animal species, we noticed that two genotypes (P[10] 341 
and P[12]) also showed a good amino acid conservation of the deduced ligand binding 342 
interface. In particular, a single residue W175 was found to be conserved among the 343 
two P[I] (P[10]/P[12]) and all P[II] RVs, suggesting an evolutionary connection among 344 
these human and animal RVs .   345 
Similar but genotype-specific glycan binding profiles among P[II] RVs. Additional 346 
binding studies for other P[II] RVs revealed similar but genotype-specific binding 347 
properties among the three major human RVs (P[4], P[6], and P[8]) and the P[19] RVs. 348 
Like the P[19] RVs, all of the other three P[II] RVs recognized the type 1 HBGA 349 
disaccharide precursor with low affinities, while VP8* of P[4] and P[8], but not of P[6], 350 
also recognized mucin cores 2, 4, and 6 (Fig. 9a-b). Since all these three major human 351 
RVs previously were shown binding to the type 1 HBGAs (23), we performed binding 352 
assays comparing the binding results with that of P[19] on three type 1 HBGA glycans 353 
(LNFPI, LNT, and LNDFHI) with or without the secretor (H) and/or Lewis fucoses. The 354 
P[6] and P[19] RVs recognized LNFPI and LNT, with the former containing the H 355 
fucose, while P[4] and P[8] RVs recognized the hexasaccharide LNDFHI that contains 356 
both H and Lewis fucoses (Fig. 9c-e). These data plus the conserved binding interface 357 
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described above suggest a potential selection pressure in the maintenance of the P[II] 358 
RVs by the host mucin cores and/or type 1 HBGAs. However, observations that 359 
additional saccharide residues changed the RV binding outcomes may explain the 360 
diverse host ranges for P[II] in different human populations and animal species. 361 
P[10] and P[19] VP8*s shared nearly identical glycan array and saliva binding 362 
profiles. To further study the genetic relationship between P[10] and P[19] RVs, we 363 
also performed glycan array and in vitro binding assays of P[10] as well as other three 364 
randomly selected P[I] RVs (P[13], P[15], and P[23]). Nearly identical saliva binding 365 
(Fig. 2c-d) and glycan array binding profiles (Fig. 10) have been observed between the 366 
P[10] and P[19] RVs, while the other tested P[I] RVs revealed completely different 367 
glycan binding profiles (data not shown). This result suggests strong selection 368 
pressures on the P[10] and P[19] genotypes by common host factor(s), such as the 369 
mucin cores and type 1 HBGAs, which may be responsible for their common host 370 
range.  371 
 372 
Discussion 373 
Three major P[II] RV genotypes, P[4], P[6], and P[8], cause the vast majority (>95%) of 374 
human infections worldwide (45). Interestingly, the fourth P[II] genotype P[19], unlike the 375 
others, is commonly found in animals (porcine) but rarely in humans (46-50). In this 376 
study, we found that the P[19] VP8* binds human milk, human saliva, and porcine 377 
mucins. The P[19] VP8* revealed a significantly lower binding profiles to the human 378 
saliva than the highly prevalent P[4] and P[8] RVs, consistent with the low prevalence of 379 
P[19] RVs in humans observed so far. We further demonstrated that the P[19] RVs 380 
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recognize the mucin cores (2, 4, and 6) and type 1 HBGA precursors as the minimal 381 
functional units. However, further modifications of these glycans with additional 382 
saccharides, such as the A, B, H, or Lewis epitopes, and even SA, could influence and 383 
further define the binding outcomes. Interestingly, this unique binding property is shared 384 
with other P[II] RVs, supported by the observation that all the other P[II] RV genotypes 385 
also recognize the mucin core and type 1 HBGA related sequences while exhibiting a 386 
genotype-specific difference.  387 
Specifically, all of the A, B, and H epitopes appear to be involved in P[19] RV binding, 388 
while the addition of the Lewis epitope (1,4-linked fucose) to these type 1 HBGA 389 
glycans completely blocked P[19] binding (Fig.3). This type of epitope blocking or 390 
masking effect may explain why the P[19] RVs rarely infect humans; 90% of the general 391 
population are Lewis-positive, leading to Lewis-negative type 1 HBGA phenotypes in 392 
only 10% of the general population (45). On the other hand, the requirement of the 393 
Lewis epitope for binding also seemed to play an important role in the high prevalence 394 
of the P[4] and P[8] RVs in humans, which was suggested by their common recognition 395 
of Lewis b (Leb) antigens containing the Lewis epitope (23). A strong association 396 
between Lewis status and P[4]/P[8] RV infection has also been reported, where P[8] 397 
infection only occurred in Lewis-positive children (31). In the current study, we further 398 
demonstrated the importance of Lewis epitopes for these two genotypes by their binding 399 
to the hexasaccharide LNDFHI (Fig.9), that contains the Lewis epitope, but not to the 400 
type 1 glycans LNFPI and LNT that lack the Lewis epitope.  401 
The differences in Lewis epitope involvement for P[II] RV binding may also play a role in 402 
human versus animal host ranges, as some animal species, such as mice and pigs, 403 
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lack Lewis antigens ((51), our unpublished data), and could explain why P[4] and P[8] 404 
RVs rarely infect animals. On the other hand, the infection of P[19] and P[6] RVs in 405 
animals may be due to their lack Lewis epitopes, leaving the mucin cores and/or the 406 
type 1 HBGA precursors readily available to bind these genotypes. As an alternative 407 
hypothesis it has been proposed, that shared HBGAs are responsible for cross-species 408 
P[11] RV transmission between humans and animals, since P[11] recognizes 409 
evolutionarily conserved type 2 HBGA precursors or intermediate products (22).  410 
The P[6] RV did not bind the mucin core glycans and bound poorly to the human adult 411 
saliva (23), but recognized the penta-saccharide LNT, containing the type 1 HBGA  412 
sequences without H and Lewis epitopes, and the hexo-saccharide LNFPI, without 413 
Lewis epitopes (Fig. 9). This result is consistent with those of another P[6] RV (strain 414 
RV3) that bound a group of long glycans containing the type 1 HBGA terminal 415 
sequences (with or without the H epitope but without the Lewis epitope) and an extra 416 
Lewis x side chain (32). In addition, a negative association between P[6] RV infection in 417 
children and the presence of the Lewis gene has been reported (31). Furthermore, in 418 
the current study, we also observed an age-specific binding pattern for P[6] RVs to 419 
saliva samples from neonates and young infants (data not shown), which is reminiscent 420 
of the age-specific host ranges in neonates and young infants found for the P[11] RVs 421 
(24, 26). Since P[6] RV infection appears independent of the Lewis epitope, we 422 
hypothesize that P[6] RVs may share a similar mechanism for age-specific host ranges 423 
as the P[11] RVs, by recognizing the HBGA precursor and/or intermediate products that 424 
may be developmentally regulated in neonates and young infants.  425 
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The finding of nearly identical saliva- and glycan-binding profiles between P[10] and 426 
P[19] suggests a potential evolutionary connection between P[10] and P[19] RVs, which 427 
may be selected by a common host factor such as the mucin cores and/or type 1 428 
HBGAs. The conserved amino acids of the deduced binding interface, particularly the 429 
exclusively conserved residue W175 between P[10]/P[12] and P[19] and other P[II] RVs 430 
(P[4], P[6], and P[8]), further supports this hypothesis. Interestingly, P[10] and P[19] 431 
have very similar host ranges, both pigs and humans, while the majority of other P[I] 432 
RVs exclusively infect animals. This observation in our view raises concern regarding 433 
the strategy to develop live, attenuated animal RV reassortant vaccines for humans, 434 
because these animal RVs, such as the bovine (P[5]) and sheep (P[15]) (52, 53), may 435 
not replicate in the human intestine due to lack of proper host receptors. Future studies 436 
to clarify this concern are urgently required.  437 
Our study raises additional issues that need to be addressed in the future. For example, 438 
based on the binding properties of P[19] and other P[II] RVs, we noted a potential 439 
binding specificity switch from simple mucin core glycans to more complex type 1 440 
HBGAs, leading to host range changes between animal (P[I]) and human (P[II]) RVs 441 
and among P[II] RVs in different human populations. However, direct evidence, 442 
including supporting structural data, for such host range switching and variations 443 
remains lacking. While mucin core 2 is commonly found in a variety of cells and tissues, 444 
mucin cores 4 and 6 sequences were only found in a very limited type of mucin, that is 445 
in human intestinal mucins (54). Thus, future studies to determine the role of mucin 446 
cores versus type 1 HBGAs in human RV host ranges are necessary. Finally, during our 447 
characterization of P[19] and other P[II] and P[I] RVs, we noted that the RV-glycan 448 
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interactions are far more complicated than previously thought. While the minimal 449 
binding units of the HBGA and/or mucin core sequences are essential for binding, 450 
further terminal or internal side chain modifications, the lengths of the glycan 451 
backbones, and repeated sequences could strongly influence or change the binding 452 
affinities and/or specificities, and therefore, the final binding outcomes. Thus, future 453 
studies are needed to define the precise amino acids within the binding interface that 454 
are responsible for specific interactions between each sugar residue and the individual 455 
P genotypes characterized in this study.  456 
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Figure Legends: 463 
Figure 1. Phylogeny, host ranges, and potential host glycan ligands for group A 464 
rotaviruses. The group A RVs have been divided into 37 P genotypes (P[1] – P[37]) 465 
based on the major surface spike protein VP4 (33). A phylogeny dividing 35 group A 466 
RVs (P[1] – P[35]) into in five P genogroups (P[I] – P[IV]), reported previously (25), is 467 
shown. The assigned human and animal hosts were based on the ranks of VP4/VP8* 468 
sequence numbers reported for individual species with only the top (internal row) and 469 
second (our row) ranks shown. It is noted that limited numbers of sequences were 470 
reported for genotypes P[10], P[18], P[20] as well as the newly identified genotypes 471 
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P[28]-P[35], and the true host species for these genotypes need to be verified in future 472 
studies. The carbohydrate ligands recognized by genotypes reported in the literature 473 
are listed, including P[1], P[2], P[3], and P[7] (9); P[4], P[6], and P[8] (13, 20, 23); P[9], 474 
P[14], and P[25] (25); P[11] (24, 26); and P[19] (in this study). Comparison of the P[7] 475 
(PDB ID: 2I2S (44)) and P[14] (PDB ID: 4DRV (21)) receptor binding sites with P[19] is 476 
in the bottom panel. The figure is modified based on data presented in previously 477 
published references (21-23, 25, 44) 478 
Figure 2. Binding profiles of P[19] VP8* with human milk and porcine mucin and a 479 
comparison of saliva binding profiles between P[10]  and P[19]VP8*s. The human 480 
milk and porcine mucin samples were fractioned through a Superdex 200 column before 481 
testing for binding to P[19] VP8* following a procedure described previously (24, 25). 482 
Binding signals peaked in the high molecular weight fractions for both human milk 483 
(panel a) and porcine mucin (panel b) samples. The P[19] VP8* also revealed a binding 484 
profile similar to that of another RV (P[10] in P[I] genogroup, panel d) among 96 adult 485 
human saliva samples tested (panel c). The ABH and Lewis statuses of the saliva 486 
donors are indicated. Each column represents the mean A450 absorbance value and the 487 
error bars represent the standard deviation for each sample tested in triplicate.  488 
 489 
Figure 3. P[19] VP8* recognizes mucin cores 2/4/6 and type 1 HBGAs. (a) A list of 490 
top glycans recognized by P[19] VP8* in a glycan array containing 610 glycans. (b)-(e)  491 
Binding to four types (1 – 4) of HBGA glycans, of which the P[19] VP8* only recognized 492 
type 1 HBGA glycans. The binding signals to the H1 trisaccharide (Fucα1-2Gal β1-493 
3GlcNAc-) were weak to moderate but significantly increased with the addition of the A- 494 
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or B-residues, whereas further addition of a β1-3 fucose (the Lewis epitope, green 495 
dashed circle) to the GlcNAc (forming Leb) completely blocked the binding. The 496 
disaccharide Galβ1-3GlcNAc of the type 1 HBGA precursor (highlighted in red dashed 497 
boxes) is believed to be essential for binding, while the terminal residues fucose, A, or B 498 
residues added to Gal (Fucα1-2Galβ1-3GlcNAc-, GalNAcα1-3(Fucα1-2)Galβ1-499 
3GlcNAc-, Galα1-3(Fucα1-2)Galβ1-3GlcNAc-) could increase the binding. (f) Among the 500 
eight mucin core glycans (core 1 to core 8) tested, only mucin cores 2, 4, and 6 501 
revealed binding signals. The disaccharide GlcNAcβ1-6GalNAc is believed to be 502 
essential for binding, which is highlighted in red dashed boxes. The ELISA was 503 
performed in triplicate and the whole experiment was repeated once. The error bars 504 
represent the standard deviations from triplicate wells. (g) Analysis with a focused array 505 
of lipid-linked sequence-defined probes, which was carried out to further determine the 506 
HBGA binding specificity of P[19] VP8*. Six pair-wise comparisons of type 1 and type 2 507 
chains with different lengths and capping moieties are shown. The P[19] VP8* 508 
recognized only the type 1 containing probes (red). The type 2 chain probes are marked 509 
green. DH represents the amino lipid that the oligosaccharide probes were linked to. ‘-’ 510 
indicates fluorescence intensity less than 1. 511 
Figure 4. NMR spectra of LNFPI and mucin core 2 in complex with P[19] VP8*. 1H 512 
NMR of P[19] VP8* (130 µM) with LNFPI (6.6 mM) is shown in (a). The LNFPI epitope 513 
map when bound to P[19] VP8* is shown in (b): dark orange, strong STD NMR effects;  514 
orange, weaker; and yellow, the weakest STD NMR effects. The STD amplification 515 
factors are shown in the box for residues that are not overlapped in the 1D STD 516 
spectrum. For 1H resonances that were overlapped in the 1D STD spectrum, further 2D 517 
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STD-TOCSY was applied. The inclusion of GlcNAc-III H6s and Gal-IV H3 in the binding 518 
epitope was based on the 2D STD-TOCSY and colored orange (data not shown). 1H 519 
NMR of mucin core 2 (6.0 mM) with P[19] VP8* (200 µM) is shown in (c) with an 520 
expanded spectral view shown at the top of the panel. ‘H6d’ indicates a downfield 521 
proton and ‘H6u’ indicates an upfield proton. The epitope map of mucin core 2 when 522 
bound to P[19] VP8* is shown in (d). The STD-TOCSY was used to add the overlapping 523 
resonances of GlcNAc-III H3/H4/H5 in the binding epitope (data not shown).   524 
Figure 5. Inhibition of P[19] RV replication in cell culture by human milk, neonatal 525 
saliva, porcine mucin, and LNFPI conjugates. A representative immunofluorescence 526 
microscopy image of MA104 cells infected with P[19] RV is shown in (a). Each green 527 
dot represents an infected cell, as shown in the enlarged panel. The plotted blocking 528 
results are shown in (b) and (c). The error bars represent standard errors from triplicate 529 
repeats, and the experiment was repeated once. The statistical significance was 530 
calculated by ANOVA, the asterisk refers to statistical difference <0.05. (b) Blocking 531 
results with neonatal saliva, human milk, and porcine mucin FPLC fractions. Human 532 
saliva samples that do (saliva (+)) and do not (saliva (-)) bind to P[19] VP8* in the ELISA 533 
binding assays were used in the blocking assay as positive and negative controls, 534 
respectively. The saliva samples were tested at 1:10 and 1:20 dilutions in PBS with a 535 
negative control containing PBS only. Serial dilutions of the human milk samples at 1:1, 536 
1:10, and 1:100 were tested. The FPLC fraction of the porcine mucin samples that 537 
showed VP8* binding (F11) was tested with an FPLC fraction (F81) that did not bind 538 
P[19] VP8* as a negative control. (c) Blocking results with BSA-conjugated LNFPI and 539 
free mucin core 2 oligosaccharide at final concentrations of 0.25, 0.5, and 1 µg/µl. 540 
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Figure 6. Chemical shift changes in P[19] VP8* upon addition of mucin core 2 (a) or 541 
LNFPI (b). Titrations were followed with two-dimensional 1H-15N HSQC spectra of 0.25 542 
mM 15N-labeled P[19] VP8* in Tris buffer collected at 20 oC on a Bruker Avance III 600 543 
MHz NMR spectrometer. NMR data shown has increasing ligand:protein ratios of 0:1 544 
(red), 2:1 (orange), 8:1 (green), and 30:1 (blue). Peaks that disappeared upon titration 545 
were circled. Surface representation of the HN chemical shift changes for P[19] VP8* 546 
with mucin core 2 (c) and LNFPI (d) was shown. The data were plotted onto the surface 547 
of a P[19] VP8* homology model with the largest changes in dark red. The chemical 548 
shift differences between 1H and 15N resonances in free- and ligand-bound proteins 549 
were determined as the weighted chemical shift change. For LNFPI, three HN cross-550 
peaks disappeared upon ligand titration and did not reappear at higher ligand 551 
concentrations. These residues, T186, E214, and C217 were set at a maximum of Δδ av 552 
= 0.25. The 2-D 1H-15N HSQC with ligand:protein ratio of 30:1 was used for the bound 553 
shifts. The protein structure of P[19] VP8* was based on a homology model using the 554 
crystal structure of DS1 (a P[4] RV, PDB ID: 2AEN) as the template and marked by 555 
using the Pymol program. (e) Plot of normalized chemical shift changes (CSC/CSC-556 
max) versus free ligand concentrations (mM). 557 
Figure 7.  Ligand-binding interface for P[19]VP8* confirmed by site-directed 558 
mutagenesis. (a) The homology model for P[19] VP8* was constructed based on the 559 
DS1 crystal structure (P[4], PDB ID: 2AEN). The surface amino acid residues with 560 
chemical shift changes in HSQC NMR titration are underlined. The amino acids 561 
corresponding to previously reported SA- or A antigen binding sites are colored yellow, 562 
while the newly identified ligand binding site is colored pink. (b) Superimposition of P[19] 563 
VP8* (in cyan) with P[3] VP8* (grey, PDB ID:1KQR). The glycan binding interfaces for 564 
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the two genotypes are colored in pink and yellow, respectively. (c) The binding results 565 
for P[19] VP8* and its mutants, each with a signal amino acid mutation at the 566 
corresponding SA-binding amino acids (V101, F144, N146, K155, D188, Y189, S190, 567 
T191), to the mucin cores are shown. Mutants with significant glycan binding A450 value 568 
changes are marked by a star (*). (d) The binding results for P[19] VP8* and its 569 
mutants, with chemical shift changes at around the sialic acid or A antigen binding site, 570 
to mucin core glycans. Single amino acid mutations of seven residues (W81, L168, 571 
H170, W175, T186, R211, E214) resulted in a complete loss of binding signals. (e) The 572 
binding results of the P[19] VP8* and its mutants at the corresponding SA-binding 573 
amino acids to the glycan of LNFPI. (f) Binding of mutations corresponding to amino 574 
acids that showed chemical shift changes to LNFPI. All seven residues that were found 575 
to be involved in mucin core binding (W81, L168, H170, W175, T186, R211, E214), and 576 
an additional residue T218, also resulted in a complete loss of binding to LNFPI. The 577 
binding assay was tested in triplicate and the entire experiment was repeated twice. The 578 
statistical significance was calculated by ANOVA analysis and the mean A450 579 
absorbance values with standard deviations are shown. 580 
Figure 8. Sequence alignment of VP8*s from reported P[19] strains. The amino 581 
acids which were deduced to interact with mucin cores and LNFPI glycans in the current 582 
study are highly conserved among all the P[19] human and porcine strains, and are 583 
marked by orange boxes. Residues that interact with sialic acid or type A HBGAs in the 584 
corresponding genotypes were marked in red, and those that interact with type 2 585 
HBGAs precursor for P[11] genotype were marked in blue. 586 
 587 
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Figure 9. Binding of P[II] RV VP8*s to mucin cores 2, 4, 6, and type 1 HBGA-588 
related glycans. (a) Binding of the P[4], P[6], and P[8] VP8*s to mucin cores 2, 4, and 589 
6. Two doses (2 or 20 µg/ml) of the mucin cores were tested. Positive binding signals 590 
were observed for P[4] and P[8], but not for P[6]. (b) Binding of the P[II] RVs to the type 591 
1 precursor disaccharide lacto-N-biose (Galβ1-3GlcNAc). Low binding signals were 592 
detected for all four P[II] RVs. (c)-(e) Binding of the P[II] RV VP8*s with the type 1 593 
HBGAs LNT, LNFPI, and LNDFPI. The P[6] and P[19] VP8*s showed positive binding to 594 
the type 1 tetrasaccharide LNT (Galβ1-3GlcNAcβ1-3Galβ1-4Glc) (c) and the LNFPI 595 
pentasaccharide (Fucα1-2 Galβ1-3GlcNAcβ1-3Galβ1-4Glc) (d) with or without the 596 
terminal fucose modification (secretor), respectively. Neither of the P[4] and P[8] VP8*s 597 
bound the LNT and LNFPI oligosaccharides (e). Adding a Lewis fucose to LNFPI results 598 
in the LNDFHI hexasaccharide (Fucα1-2 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc), 599 
which led to negative P[6] and P[19] VP8* binding, but positive P[4] and P[8] VP8* 600 
binding. The mean A450 absorbance values from three replicates with standard 601 
deviations are shown. 602 
 Figure 10. P[10] from P[I] showed a similar glycan binding pattern to P[19] VP8*. 603 
A glycan array analysis was performed for P[10] in comparison with P[19]. Relative 604 
Fluorescent Units (RFU) of GST-VP8* at 200 µg/ml binding to 610 glycans are shown, 605 
where RFU corresponds to the strength of binding to individual glycans. The identities of 606 
the 610 glycans in the array are available at 607 
http://www.functionalglycomics.org/static/consortium/resources/resourcecoreh8. The 608 
P[10] VP8* (panel b)revealed a similar binding profile, with a dozen identical, high 609 
reactive glycans, to that of P[19] VP8*(panel a). The top fifteen ranked glycans for each 610 
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of the two genotypes are shown on the right. Thirteen of the fifteen glycans (marked in 611 
bold) were shared by both P[19] and P[10]. The error bars represent the standard 612 
deviation from four replicate wells. 613 
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100 110 120 130 140 150 160 170 180 190 200 210 220
|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
RRV|P[3] 100 DRWLATILVEPNVTSETRSYTLFGTQEQITIAYASQTQWKFIDVVKTTQNGSYS-QYGPLQSTPKLYAVMKHN-GKIYTYNGETPNVTTK--YYSTTNYDSVNMTAFCDFYIIPREEESTCTEYINNGL
NCDV|P[1] 100 NRWLATILIEPNVQQVERTYTLFGQQVQVTVSNDSQTKWKFVDLSKQTQDGNYS-QHGSLLSTPKLYGVMKHG-GKIYTYNGETPNATTG--YYSTTNFDTVNMTAYCDFYIIPLAQEAKCTEYINNGL
SA11|P[2] 100 DRWLATILIEPNVQSENRTYTIFGIQEQLTVSNTSQDQWKFIDVVKTTANGSIG-QYGSLLSSPKLYAVMKHN-EKLYTYEGQTPNARTG--HYSTTNYDSVNMTAFCDFYIIPRSEESKCTEYINNGL
CRW8|P[7] 100 DRWLATILIEPNVQTTNRIYNLFGQQVTLSVENTSQTQWKFIDVSKTTPTGNYT-QHGSLFSTPKLYAVMKFS-GRIYTYNGTTPNATTG--YYSTTNYDTVNMTSFCDFYIIPRNQEEKCTEYINHGL
L338|P[18] 100 NRWLAIILVEPDVPTEERTYTLFGQQAQITVANDSQLKWKFIVVSKQTLDGAYA-QYGPLLSATKLYAVMKHS-GRIYTYSGETPNATTA--YYSTTNYDTVNMKAYCHFYIIPRTQESKCTEYINTGL
69M|P[10] 100 NRWLATILVEPGVASTTRTYTLFGIQEQITVENSSNTKWKFIDLMKTTSSGTYT-QHSPLLSEPKLYGIMKHG-GQLWTYNGETPNAITN--GYPTTNYDSVNMTSFCNFYIIPRSQESVRTGYINNGL
H-2|P[12] 100 NRWLATVLVEPNVVTTVRTYTLFGVQEQISVENNSTTKWKFMNLIKTTLSGNFT-LYSTLLSEPKLHGIMKHG-GQLWVYNGETQTLLLQ--DYVTSNYDSLTMTSFCDFYIIPRSQESTCTEYINNGL
WC3|P[5] 100 GRWLSVILIEPGVTSETRTYTMFGSSKQVLVSNASDTKWKFVEMMKTAIDGDYA-EWGTLLSDTKLYGMMKYG-KRLFIYEGETPNATTK--RYIVTNYASVEVRPYSDFYIISRSQESACTEYINNGL
A46|P[13] 100 DMWLVIILVEPNVPQELRLYTLFGQQVNLTIENTSQTKWKFIDFRKRSQNDTYI-LENALLSETKLQAAMKYG-GKLFTFTGDTPNAAPQEWGYTTNNYSAISIKSLCDFYIVPRLPRETCRNYINQGL
Lp14|P[15] 100 NRWLATILIEPNVPETTRNYTLFGETASISVANPSQSKWRFVDVVKTTANGTYS-QYGPLLSDTKLYGVMKYN-GKLYTYNGETPNATTK--YYSTTNYDSVNMTSYCDFYIIPRAQESKCTEYVNNGL
Eb|P[16] 100 DRWIATIAIEPNVSKTKRTYTLFGITEQLTVENSYADKWKFIDFLKASTNGSYA-RYNILLSSTKLCAVAKHT-DRLYSYIRETPNAGQA--YYAFSHN-IFNLTAHCDFYIIPWAQQSLCTQYINTGL
EHP|P[20] 100 DRWLATILIEPNVASTTRTYTIFGSKEAITVENTSQNKWKFIDLAKTSLTGSYS-QYGILLSKPKLYAIMKRS-GYLYTYSGETPDAITD--YYTTTNYDSVNMTAYCDFYIIPWAQEALCTQYINNGL
Hg18|P[21] 100 NKWFATILIEQDVVAESRTYTIFGKTESIQAENTSQTEWKFIDIIKTTQDGTYS-QYGPLVLSTKLYGVMKYG-GRLYAYIGHTPNATPG--HYTIANYDTMEMSIFCEFYIMPRSQEAQCTEYINSGL
160-01|P[22] 100 DIWLVIILVEPNVPQGSRTYTIFGQQKSLMIENTSQTKWKFIDFIKESQGGTYV-PNDTLLSETKLQAAMKYG-QRLFTFIGNTPNSAPQERGYTTNNYSTINVTSLCDFYIVPRTPREVCRNYINHGL
A34|P[23] 100 DRWLATILIEPNVTSQSRTYTLFGHQEQITVENVSTTKWKFVDLAKTDINGTFT-QHGPLLSDTKLHGVMKFS-GRLYTYNGETPNATIG--YYTTTNYDTVNMVSHCDFYIIPRSEENTCTNYINNGL
TUCH|P[24] 100 DRWLATILIEPNVAAETRTYTLFGVQEQISISNTSSTKWKFVDLVKTSLTGTYS-QYGPLLSDTKLYGAMKYS-GRIYTYEGETPNAATG--YYSTTNYDSVNMTAFCDFYIIPRSQESTCTNYINNGL
134-04-15|P[26] 100 SRWLAIILVEPNVSQETRTYTIFGQQVQLQVENVSQTKWKFIDVSKTSQGGSYT-QYSTLLSNTKLDAVIKYG-GKVFTYNGETPSATSG--QYTTTNYEAIVMTLFCDFYIIPRTQEETCTNYINHGL
344-04-1|P[27] 100 DQWIAAILIEPNTNTITKNYTLFGKQEQIEVSNAS-SKWKFVDLIKKTVDGSFT-QRGPLLSDTKLYAVMKHG-SQVFTYGGETPNAATV--GYATLNYSELIIAVYCDFYIIPRAQEKQCTSFINNGL
P21-5|P[28] 100 DQWIAAILIEPNTSTTTRSYALFGKQESIEVSNPS-SRWKFVELVKHTVDGGFT-QHGPLLSNTKLYGVMKYG-QKVFTYQGETPNATTD--YYTVSNYSELIITVYCDFYIISRAQQAECTNFINNGL
AzuK-1|P[29] 100 NIWMAAIIIEPNLSAEQRTYRIYDEDVELLVDNASRTKWKIVDLYKTQQSGQYVRQNWRIYTAYKLYGIRIVD-TKLQSYGGETPNLSIIT--TTVTNYSNVEITTLSNFFIISSNNTEKCTTYMNQGL
IRL|P[32] 100 NRWLAIILVEPGVTQTTREYNVFGERIQLQVENTHQTKWKFIDISRANQSDSYA-QYGPLLSDTKLYAAMKYN-GLICTYVGETPNARTD--QYSTTNYRDVEMTIFCDFYIIPRAQENICTNYINNGL
Dai-10|P[33] 100 NRWLAVILIEPGVNQETRNYNIFGKQEQLVVSNTSSTQWKFVDAIKTSEDGSYN-QHGQLLSTNKLYAVMKSG-GRVYTYEGTTPNARTG--FYTTSNYSTVKVNVLCDFYIIPLAQESKCTEYINNGL
FGP51|P[34] 100 NKWIAAIMIEPSTISVTKNYTLFGQQEQVQVSNTSTTKWKLVELVKQTQNGVYT-QHGELLSDTKLYGVMKYG-GLVCTYKGETPNATTD--QYTTSNYSELSIAVHCDFYIISRAQEAECTRYINYGL
MC345|P[19] 100 DVWVAIISIEPNVNSESRQYSLFGVNKQITVVNTS-NKWKFMEMFRNNSNAEFQ-HKRTLTSSTKLVGILKHG-GRLWTYHGETPNATTD--YSTTSNLNEISVTTYAEFYIIPRSQESKCTEYINTGL
ST3|P[6] 100 DIWIALLLVEPNVTNQSRQYTLFGETKQITIENNT-NKWKFFEMFRSNVSSEFQ-HKRTLTSDTKLAGFLKHY-NSVWTFHGETPHATTD--YSSTSNLSEVETTIHVEFYIISRSQESKCVEYINTGL
L26|P[4] 100 DFWTAVIAVEPRVSQTNRQYILFGENKQFNIENNS-DKWKFFEMFKGSSQSNFS-NRRTLTSNNRLVGMLKYG-GRVWTFHGETPRATTD--SSNTADLNNISIVIHSEFYIIPRSQESKCNEYINNGL
Wa|P[8] 100 DFWTAVVAIEPHVNPVDRQYTIFGESKQFNVSNDS-NKWKFLEMFRSSSQNEFY-NRRTLTSDTRFVGILKYG-GRVWTFHGETPRATTD--SSSTANLNNISITIHSEFYIIPRSQESKCNEYINNGL
HAL1166|P[14] 100 DRWFACVLVEPNVQNTQREYVLDGQTVQLQVSNNSSTLWKFILFIKLEKNGAYS-QYSTLSTSNKLCAWMKRE-GRVYWYAGTTPNASES--YYLTINNDNSNVSCDAEFYLIPRSQTELCTQYINNGL
K8|P[9] 100 DRWFACVLVEPNVQNTQRQYVLDGQNVQLHVSNDSSTSWKFILFIKLTPYGTYT-QYSTLSTPHKLCAWMKRD-NRVYWYQGATPNASES--YYLTINNDNSNVSSDAEFYLIPQSQTAMCTQYINNGL
Dhaka6|P[25] 100 DRWFACIIVEPNVSLQSRDYVLDGQIVQLQVDNTSNTMWKFILFIKLTKSGNYS-QYSSLSTNHKLCAWIKRD-GRVYWFDGTVPNSSDN--YYLTINNDNSIISSDVDFYLIPRTQTDSCRRYINNGL
B233|P[11] 100 TFWMFTYLVLPNTAQTNVTVNVMNETVNISIDNSG-STYRFVDYIKTSSTQAYG-SRNYLNTAHRLQAYRRDGDGNISNYWGADTQGDLR-VGTYSNPVPNAVINLNADFYVIPDSQQETCTEYIRGGL
993-83|P[17] 100 NKKYACVMLAPNTEEGDKQYTILGRQITINLGNTDQNRYKFFDLASEN-GETYS-KIQELLTPNRLNAFMKDQ-GRLYVYHGTVPNISTG--YYTLDDIANVQTNIKCNYYIVPKSQTQQLEDFLKNGL
Ch-02V0002G3|P[30] 100 DQKYARVMLLPNTADGNKQYTILGHRVTINLGNTNSNMYKFCDLVSHN-GTTYT-KVEELVTPHGLNAFMKDQ-GKLYLYNGTVPNVQQV--YYTLANIENVQTNIKCNYYIVPKTQTGQLEDYIKNGL
Ch-06V0661|P[31] 100 NKKFACVMLPPNTPESDRQYTILGKQITIRLGNTDTVNYKFCDLLSND-GITYT-KSIELITPHRLNAFMKDA-GKLYAYSGTVPTIKKE--YHTLDNIENVQTNITCEYYIVPNSQVSTLEEYLKNGL
Tu-03V0002E10|P[35] 100 NRKYACVLMPPNTGNGDKQYTILGKQITINLGNTDQSKYKFFDLVSTD-GSTYS-KIQELTTPHRLNAFMKDQ-GRLYVYIGIVPNISTG--YYTLDDIEHVQTNIKCNYYIVSQSQTQQLEDFLKNGL
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Figure 10 
Chart 
Number Glycan structure 
Average 
RFU 
604 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 5399 
133 GlcNAcb1-6(Galb1-3)GalNAca-Sp8  3887 
567 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 3035 
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp14 2960 
525 Gala1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAc-Sp14 1633 
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 1587 
66 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 1024 
65 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 950 
193 GlcNAcb1-6GalNAca-Sp14 847 
506 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-6GalNAca-Sp14 807 
558 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Man a1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24 505 
505 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)GalNAca-Sp14 444 
176 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 400 
583 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 306 
585 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 302 
Chart 
Number Glycan structure 
Average 
RFU 
133 GlcNAcb1-6(Galb1-3)GalNAca-Sp8  7535 
604 GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 6576 
66 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp10 6174 
65 Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glcb-Sp8 6018 
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 4912 
567 Galb1-3GlcNAcb1-6(Galb1-3)GalNAc-Sp14 4700 
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp14 3786 
176 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 3015 
558 GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Man a1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp24 2784 
585 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 2531 
583 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-
2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-
6)GlcNAcb-Sp24 2372 
587 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-
3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-
4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 1635 
505 Fuca1-2Galb1-3GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)GalNAca-Sp14 1626 
549 GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 1185 
564 
GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp25 1082 
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